EP Patent

EP2201018B1 — Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-ý7-(2-morpholin-4-yl-ethoxy)imidazoý2,1-b¨ý1,3¨benzothiazol-2-yl¨phenyl}urea, compositions thereof, and uses therewith

Assigned to Ambit Bioscience Corp · Expires 2016-03-16 · 10y expired

What this patent protects

Patent listed against quizartinib-dihydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
EP2201018B1
Jurisdiction
EP
Classification
—
Expires
2016-03-16
Drug substance claim
No
Drug product claim
No
Assignee
Ambit Bioscience Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.